Oral fenofibrate for hyperbilirubinemia in term neonates: A single-blind randomized controlled trial.
Fenofibrate
bilirubin
neonatal jaundice
Journal
Journal of clinical and translational science
ISSN: 2059-8661
Titre abrégé: J Clin Transl Sci
Pays: England
ID NLM: 101689953
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
09
2022
revised:
18
01
2023
accepted:
28
02
2023
medline:
1
5
2023
pubmed:
1
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
Hyperbilirubinemia is common in the neonatal period; however, delayed diagnosis or inadequate treatment can cause irreparable damage to the neonates. We aimed to evaluate the efficacy of oral fenofibrate for hyperbilirubinemia in term neonates. This single-blind randomized controlled trial included 86 term neonates aged 3-7 days, with birth weight ≥2500 g, admitted to Bandar Abbas Children's Hospital, Bandar Abbas Iran, from July 23, 2019, to July 22, 2020. The fenofibrate group received 10 mg/kg oral fenofibrate and phototherapy, while controls only received phototherapy. Serum total bilirubin was measured at 24 and 48 h and at the time of discharge. Hospital length of stay was also noted. The two study groups were comparable regarding age, gender, gestational age, birth weight, and baseline total serum bilirubin levels. Serum total bilirubin levels at 48 h ( A single dose of oral fenofibrate reduced total serum bilirubin in term neonates with hyperbilirubinemia without any side effects; however, this effect was more prominent after 48 h.
Sections du résumé
Background
UNASSIGNED
Hyperbilirubinemia is common in the neonatal period; however, delayed diagnosis or inadequate treatment can cause irreparable damage to the neonates. We aimed to evaluate the efficacy of oral fenofibrate for hyperbilirubinemia in term neonates.
Methods
UNASSIGNED
This single-blind randomized controlled trial included 86 term neonates aged 3-7 days, with birth weight ≥2500 g, admitted to Bandar Abbas Children's Hospital, Bandar Abbas Iran, from July 23, 2019, to July 22, 2020. The fenofibrate group received 10 mg/kg oral fenofibrate and phototherapy, while controls only received phototherapy. Serum total bilirubin was measured at 24 and 48 h and at the time of discharge. Hospital length of stay was also noted.
Results
UNASSIGNED
The two study groups were comparable regarding age, gender, gestational age, birth weight, and baseline total serum bilirubin levels. Serum total bilirubin levels at 48 h (
Conclusions
UNASSIGNED
A single dose of oral fenofibrate reduced total serum bilirubin in term neonates with hyperbilirubinemia without any side effects; however, this effect was more prominent after 48 h.
Identifiants
pubmed: 37125058
doi: 10.1017/cts.2023.35
pii: S2059866123000353
pmc: PMC10130838
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e85Informations de copyright
© The Author(s) 2023.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Breastfeed Med. 2016 May;11:180-5
pubmed: 27057645
Pediatrics. 2018 Feb;141(2):
pubmed: 29305393
Pediatrics. 2004 Jul;114(1):297-316
pubmed: 15231951
PLoS One. 2018 May 11;13(5):e0197113
pubmed: 29750802
ChemMedChem. 2019 Jun 5;14(11):1051-1066
pubmed: 30957432
J Perinatol. 2021 Apr;41(4):865-872
pubmed: 33070152
BMJ. 1995 Feb 4;310(6975):298
pubmed: 7866172
Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1319-30
pubmed: 19018684
Acta Paediatr. 2018 Apr;107(4):611-619
pubmed: 29119603
BMC Gastroenterol. 2007 Nov 28;7:44
pubmed: 18045488
Pediatrics. 2012 Oct;130(4):e886-90
pubmed: 22966025